Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

42.57

Mkt cap

278B

Volume

213K

High

43.31

P/E Ratio

29.63

52-wk high

43.96

Low

42.56

Div yield

N/A

52-wk low

29.20

Viking Therapeutics and Roche Holdings saw significant stock price increases due to developments in the GLP-1 weight-loss drug market, while Novo Nordisk's stock dropped.

Portfolio Pulse from

March 12, 2025 | 4:30 pm

Roche has partnered with Zealand Pharma to co-develop and co-commercialize petrelintide, a novel amylin analog. This partnership strengthens Roche's obesity pipeline and provides Zealand Pharma with substantial financial benefits and a strong commercialization partner.

Portfolio Pulse from

March 12, 2025 | 2:30 pm

Roche (RHHBY) has entered into a $5.3 billion collaboration and licensing agreement with Zealand Pharma for an obesity drug candidate.

Portfolio Pulse from

March 12, 2025 | 1:45 pm

Roche has entered a $5.3 billion deal with Zealand Pharma to develop an obesity drug candidate, causing Zealand Pharma's shares to rise by 29% and Roche's by 4.6%.

Portfolio Pulse from

March 12, 2025 | 11:15 am

Roche has announced a significant $5.3 billion licensing and development deal with Zealand Pharma, marking a major move into the weight-loss sector.

Portfolio Pulse from

March 12, 2025 | 9:45 am

Roche has entered into an exclusive collaboration and licensing agreement with Zealand Pharma to co-develop and co-commercialize petrelintide, a potential therapy for overweight and obesity.

Portfolio Pulse from

March 12, 2025 | 6:15 am

Zealand Pharma and Roche have entered a collaboration to co-develop and co-commercialize petrelintide for treating overweight and obesity. Zealand Pharma will receive up to $5.3 billion, including $1.65 billion upfront. Profits and losses will be shared equally in the U.S. and Europe.

Portfolio Pulse from

March 12, 2025 | 6:15 am

Roche has launched the Roche Genentech Innovation Center Boston at Harvard's Enterprise Research Campus in Allston, enhancing their partnership in disease biology, engineering, and AI/ML.

Portfolio Pulse from

March 07, 2025 | 6:15 am

The FDA has accepted Roche's supplemental New Drug Application (sNDA) for Gazyva to treat lupus nephritis, based on positive data from a late-stage study showing a complete renal response benefit.

Portfolio Pulse from

March 05, 2025 | 5:00 pm

The FDA has accepted Roche's supplemental Biologics License Application for Gazyva/Gazyvaro for treating lupus nephritis, based on positive phase III study results. A decision is expected by October 2025.

Portfolio Pulse from

March 05, 2025 | 6:15 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.